EUVIMEDEUVIMED entdecken
Open Access

T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy

Mark Behar iD, Kyung K Peck iD, Onur Yildirim iD, Jamie Tisnado iD, Atin Saha iD, Julio Arevalo-Perez iD, Eric Lis iD, Yoshiya Yamada iD, Andrei I Holodny iD, Sasan Karimi iD

American Journal of Neuroradiology · 2023

DOI: 10.3174/ajnr.a8057 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Neuroradiology, 2023. Verfasst von Mark Behar und 9 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New…. Hauptthemen laut MEDLINE: Spinal Neoplasms, Brain Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Bayer HealthCare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND PURPOSE: Current imaging techniques have difficulty differentiating treatment success and failure in spinal metastases undergoing radiation therapy. This study investigated the correlation between changes in dynamic contrast-enhanced MR imaging perfusion parameters and clinical outcomes following radiation therapy for spinal metastases. We hypothesized that perfusion parameters will outperform traditional size measurements in discriminating treatment success and failure. MATERIALS AND METHODS: This retrospective study included 49 patients (mean age, 63 [SD, 13] years; 29 men) with metastatic lesions treated with radiation therapy who underwent dynamic contrast-enhanced MR imaging. The median time between radiation therapy and follow-up dynamic contrast-enhanced MR imaging was 62 days. We divided patients into 2 groups: clinical success (n = 38) and failure (n = 11). Failure was defined as PET recurrence (n = 5), biopsy-proved (n = 1) recurrence, or an increase in tumor size (n = 7), while their absence defined clinical success. A Mann-Whitney U test was performed to assess differences between groups. RESULTS: The reduction in plasma volume was greater in the success group than in the failure group (-57.3% versus +88.2%, respectively; P < .001). When we assessed the success of treatment, the sensitivity of plasma volume was 91% (10 of 11; 95% CI, 82%-97%) and the specificity was 87% (33 of 38; 95% CI, 73%-94%). The sensitivity of size measurements was 82% (9 of 11; 95% CI, 67%-90%) and the specificity was 47% (18 of 38; 95% CI, 37%-67%). CONCLUSIONS: The specificity of plasma volume was higher than that of conventional size measurements, suggesting that dynamic contrast-enhanced MR imaging is a powerful tool to discriminate between treatment success and failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spinal NeoplasmsBrain NeoplasmsMaleHumansMiddle AgedRetrospective StudiesSensitivity and SpecificityMagnetic Resonance ImagingPerfusion ImagingContrast Media

Substanzen

Contrast Media

Autor:innen und Institutionen

  • From the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Medical Physics (K.K.P.), Memorial Sloan Kettering Cancer Center, New York, New York.
  • Department of Radiation Oncology (Y.Y.), Memorial Sloan Kettering Cancer Center, New York, New York.
  • From the Department of Radiology (M.B., K.K.P., O.Y., J.T., A.S., J.A.-P., E.L., A.I.H., S.K.), Memorial Sloan Kettering Cancer Center, New York, New York holodnya@mskcc.org.
  • Department of Radiology (A.I.H.), Weill Medical College of Cornell University, New York, New York.
  • Department of Neuroscience (A.I.H.), Weill-Cornell Graduate School of the Medical Sciences, New York, New York.

ORCID-Profile: Mark Behar, Kyung K Peck, Onur Yildirim, Jamie Tisnado, Atin Saha, Julio Arevalo-Perez, Eric Lis, Yoshiya Yamada, Andrei I Holodny, Sasan Karimi

Förderung

  • NCI NIH HHS
  • Bayer HealthCare

Zitieren

APA

Behar, M., Peck, K. K., Yildirim, O., Tisnado, J., Saha, A., Arevalo-Perez, J., Lis, E., Yamada, Y., Holodny, A. I., & Karimi, S. (2023). T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy. American Journal of Neuroradiology. https://doi.org/10.3174/ajnr.a8057

Vancouver

Behar M, Peck KK, Yildirim O, Tisnado J, Saha A, Arevalo-Perez J, et al. T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy. American Journal of Neuroradiology. 2023. doi:10.3174/ajnr.a8057

BibTeX
@article{Behar2023,
  author = {Behar, Mark and Peck, Kyung K and Yildirim, Onur and Tisnado, Jamie and Saha, Atin and Arevalo-Perez, Julio and Lis, Eric and Yamada, Yoshiya and Holodny, Andrei I and Karimi, Sasan},
  title = {T1-Weighted, Dynamic Contrast-Enhanced MR Perfusion Imaging Can Differentiate between Treatment Success and Failure in Spine Metastases Undergoing Radiation Therapy},
  journal = {American Journal of Neuroradiology},
  year = {2023},
  doi = {10.3174/ajnr.a8057}
}
Kostenlos starten →